Publications from the Colla Laboratory
Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation. Rodriguez-Sevilla JJ, Adema V, Garcia-Manero G, Colla S. Cell Reports Medicine 2023;4(2):100940. doi: 10.1016/j.xcrm.2023.100940. PMID: 36787738.
A machine learning-based method for automatically identifying novel cells in annotating single cell RNA-seq data. Li Z, Wang Y, Ganan-Gomez I, Colla S, Do KA. Bioinformatics 2022;38(21):4885-4892. doi: 10.1093/bioinformatics/btac617. PMID: 36083008
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Lancet Haematol. 2022;9(10):e756-e765. doi: 10.1016/S2352-3026(22)00216-2. PMID: 36063832.
Targeting the EIF2AK1 signaling pathway rescues red blood cell production in SF3B1-mutant myelodysplastic syndromes with ringed sideroblasts. Adema V, Ma F, Kanagal-Shamanna R, Thongon N, Montalban-Bravo G, Yang H, Peslak SA, Wang F, Acha P, Sole F, Lockyer P, Cassari M, Maciejewski JP, Visconte V, Ganan-Gomez I, Song Y, Bueso-Ramos C, Pellegrini M, Tan TM, Bejar R, Carew JS, Halene S, Santini V, Al-Atrash G, Clise-Dwyer K, Garcia-Manero G, Blobel GA, Colla S. Blood Cancer Discovery 2022 3(6):564-567. doi: 10.1158/2643-3230.BCD-21-0220. PMID: 35926182.
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Wei Y, Kanagal-Shamanna R, Zheng H, Bao N, Lockyer PP, Class CA, Darbaniyan F, Lu Y, Lin K, Yang H, Montalban-Bravo G, Ganan-Gomez I, Soltysiak KA, Do KA, Colla S, Garcia-Manero G. Leukemia 2022;36(8):2097-2107. doi: 10.1038/s41375-022-01605-1. PMID: 35697791
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Nature Medicine 2022 Mar;28(3):557-567. doi: 10.1038/s41591-022-01696-4. PMID: 35241842
Hematopoiesis under telomere attrition at the single-cell resolution. Thongon N, Ma F, Santoni A, Marchesini M, Fiorini E, Rose A, Adema V, Ganan-Gomez I, Groarke EM, Gutierrez-Rodrigues F, Chen S, Lockyer P, Schneider S, Bueso-Ramos C, Montalban-Bravo G, Class CA, Soltysiak KA, Pellegrini M, Sahin E, Bertuch AA, DiNardo CD, Garcia-Manero G, Young NS, Dwyer K, Colla S. Nature Communications 2021;12(1):6850. doi: 10.1038/s41467-021-27206-7. PMID: 34824242
Telomere dysfunction instigates inflammation in inflammatory bowel disease. Chakravarti D, Lee R, Multani AS, Santoni A, Keith Z, Hsu WH, Chang K, Reyes L, Rashid A, Wu CJ, Li J, Zhang J, Shim HS, Chandra K, Deng P, Spring DJ, Nielsen OH, Riis LB, Mayigegowda KK, Blutt SE, Zhang J, Younes M, DuPont A, Thirumurthi S, Vilar E, Estes MK, Colla S, Shroyer NF, DePinho RA. Proc Natl Acad Sci., USA 2021;118(29):e2024853118. doi: 10.1073/pnas.2024853118. PMID: 34253611
Activating somatic and germline TERT promoter variants in myeloid malignancies. Nofrini V, Matteucci C, Pellanera F, Gorello P, Di Giacomo D, Lema Fernandez AG, Nardelli C, Iannotti T, Brandimarte L, Arniani S, Moretti M, Gili A, Roti G, Di Battista V, Colla S, Mecucci C. Leukemia 2021;35(1):274-278. doi: 10.1038/s41375-020-0837-6. PMID: 32366939
KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Wei Y, Zheng H, Bao N, Jiang S, Bueso-Ramos CE, Khoury J, Class C, Lu Y, Lin K, Yang H, Ganan-Gomez I, Starczynowski DT, Do KA, Colla S, Garcia-Manero G. Blood Adv. 2018;2(19):2491-2504. doi: 10.1182/bloodadvances.2018024166. PMID: 30275007
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Oncotarget 2018;9(11):9714-9727. doi: 10.18632/oncotarget.23882. PMID: 29515765.
Dysfunctional telomeres and hematological disorders. Fiorini E, Santoni A, Colla S. Differentiation 2018;100:1-11. doi: 10.1016/j.diff.2018.01.001. Epub 2018 Jan 4. PMID: 29331736.
RNA processing: a new player of genomic instability in multiple myeloma. Marchesini M, Fiorini E, Colla S. Oncoscience 2017 Sep 21;4(7-8):73-74. doi: 10.18632/oncoscience.361. eCollection 2017 Jul. PMID: 28966938
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, Mistry N, Jiang S, Bao N, Marchica V, Neri A, Bueso-Ramos C, Wu CJ, Zhang L, Liang H, Peng X, Giuliani N, Draetta G, Clise-Dwyer K, Kantarjian H, Munshi N, Orlowski R, Garcia-Manero G, DePinho RA, Colla S. Cancer Cell 2017;32(1):88-100.e6. doi: 10.1016/j.ccell.2017.05.011. Epub 2017 Jun 29. PMID: 28669490
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong LN, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood LD, Sgambato A, Agaimy A, Maitra A, Roberts CW, Wang H, Viale A, DePinho RA, Draetta GF, Chin L. Nature 2017;542(7641):362-366. doi: 10.1038/nature21064. PMID: 28178232
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Am J Hematol. 2017;92(4):351-358. doi: 10.1002/ajh.24650. PMID: 28076892
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo CD, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA.
Lancet Oncol. 2017;18(1):100-111. doi: 10.1016/S1470-2045(16)30626-X. PMID: 27923552
Down-regulation of EZH2 expression in myelodysplastic syndromes. Cabrero M, Wei Y, Yang H, Ganan-Gomez I, Bohannan Z, Colla S, Marchesini M, Bravo GM, Takahashi K, Bueso-Ramos C, Garcia-Manero G. Leuk Res. 2016;44:1-7. doi: 10.1016/j.leukres.2016.02.009. PMID: 26970171
Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. Darman RB, Seiler M, Agrawal AA, Lim KH, Peng S, Aird D, Bailey SL, Bhavsar EB, Chan B, Colla S, Corson L, Feala J, Fekkes P, Ichikawa K, Keaney GF, Lee L, Kumar P, Kunii K, MacKenzie C, Matijevic M, Mizui Y, Myint K, Park ES, Puyang X, Selvaraj A, Thomas MP, Tsai J, Wang JY, Warmuth M, Yang H, Zhu P, Garcia-Manero G, Furman RR, Yu L, Smith PG, Buonamici S. Cell Rep. 2015;13(5):1033-45. doi: 10.1016/j.celrep.2015.09.053. PMID: 26565915